173 related articles for article (PubMed ID: 32924071)
1. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
Prieto Prieto JC; Vallejo Casas JA; Hatzimichael E; Fotopoulos A; Kiortsis DN; Sioka C
Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of baseline
Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
Ding CY; Guo Z; Sun J; Yang WP; Li TR
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
[No Abstract] [Full Text] [Related]
6. Can metabolic tumor parameters on primary staging
Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
[TBL] [Abstract][Full Text] [Related]
7. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
10. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
12. Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.
Ben Bouallègue F; Tabaa YA; Kafrouni M; Cartron G; Vauchot F; Mariano-Goulart D
Med Phys; 2017 Sep; 44(9):4608-4619. PubMed ID: 28513853
[TBL] [Abstract][Full Text] [Related]
13. [Value of
Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
15. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma.
Xie M; Zhai W; Cheng S; Zhang H; Xie Y; He W
Hematology; 2016 Mar; 21(2):99-105. PubMed ID: 26183456
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.
Albano D; Bosio G; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):87-96. PubMed ID: 30276438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]